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Abstract: Recent epidemiological studies and animal experiments have demonstrated that 
nonsteroidal anti-inﬂ  ammatory drugs (NSAIDs) reduce the incidence of colorectal carcinoma. 
Cyclooxygenase (COX) is the principal target of NSAIDs. COX is the ﬁ  rst oxidase in the 
process of prostaglandin production from arachidonic acid. COX enzyme may be involved 
in the initiation and/or the promotion of carcinogenesis due to NSAIDs inhibition of COX. 
Lipoxygenase (LOX) is also an initial enzyme in the pathway for producing leukotrienes 
from arachidonic acid. Similar to COX, LOX enzyme may also be involved in the initiation 
and/or promotion of carcinogenesis. Peroxisome proliferator activator-receptor (PPAR)-γ is a 
ligand-activated transcriptional factor belonging to the steroid receptor superfamily. PPAR-γ 
plays a role in both adipocyte differentiation and carcinogenesis. PPAR-γ is one target for cell 
growth modulation of NSAIDs. In this review, we report the expression of COX-2, LOX and 
PPAR-γ in human prostate cancer tissues as well as the effects of COX-2 and LOX inhibitors 
and PPAR-γ ligand.
Keywords: cyclooxygenase, lipoxygenase, peroxisome proliferator activator-receptor-γ, 
prostate cancer
Introduction
Prostate cancer (PC) comprises 32% of all cancers in American men and is on the 
increase worldwide. Because of increased screening, PC is frequently diagnosed at a 
clinically localized stage, making it amenable to the therapy. Nevertheless, it remains 
the second most common cause of cancer death in men. These patients generally 
respond to androgen deprivation therapy, but the vast majority eventually experi-
ence disease progression and become refractory to sustained hormonal manipulation. 
Typically, such patients progress with a rise in their serum prostate-speciﬁ  c antigen 
levels. Unfortunately, standard therapeutic options at this stage of disease are limited, 
and while there has been some success with chemotherapy for hormone-refractory PC 
patients, the response is generally short-lived (Oh and Kantoff 1998).
Nonsteroidal anti-inﬂ  ammatory drugs (NSAIDs) have anticancer effects for the 
hormone-refractory PC patient, thus, attracting a great deal of attention. The typical 
target of NSAIDs is cyclooxygenase (COX). In recent reports, a number of patients 
have had signiﬁ  cantly low risks of colorectal cancer while they continued using 
NSAIDs typiﬁ  ed by aspirin. Consequently, the suppression of carcinogenesis by 
administering NSAIDs has come into focus. It was also reported that the size and 
number of adenoma were markedly reduced when sulindac, a type of NSAIDs was 
given to patients with familial adenomatous polyposis, a high risk group for colorectal 
cancer (Sano et al 1995).
It is known that NSAIDs inhibit the activity of COX and production of prosta-
glandin. NSAIDs also stimulate peroxisome proliferator activator-receptor (PPAR)-γ 
and inhibit the production of chemical mediators such as tumor necrosis factor-α, Biologics: Targets & Therapy 2008:2(4) 726
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interleukin-1β and interleukin-6 through the expression of 
PPAR-γ in leukocytes. PPAR-γ is thus a promising target for 
cell growth modulation by NSAIDs.
In this review, we discuss the possibility that the target of 
arachidonic acid pathway metabolite may be a new anticancer 
strategy for human PC.
Arachidonic acid pathway 
(cyclooxygenase and lipoxygenase)
The metabolism of arachidonic acid by either COX pathway 
or lipoxygenase (LOX) pathway generates eicosanoids, 
which have been implicated in the pathogenesis of a variety 
of human diseases, including cancer, and are considered 
important in tumor promotion, progression, and metastasis 
(Yoshimura et al 2003).
COX is the ﬁ  rst enzyme in the pathway for producing 
prostaglandin (PG) and thromboxane (Tx) from arachidonic 
acid, and can occur as three isoforms, COX-1, COX-2, and 
COX-3. The enzymes of both COX-1 and COX-2 are trans-
formed from the cell membrane phospholipid to arachidonic 
acid by the phospholipaseA2, and then transform arachidonic 
acid to PGH2 through PGG2 (Figure 1). COX-1 occurs 
in tissues and cells and works to protect the cell. COX-2 
expresses momentarily and strongly in response to growth 
factors and some endotoxins. It is involved with inﬂ  amma-
tion, cell proliferation and differentiation (Xie et al 1991). 
Recently, COX-2 has also been shown to play an important 
role in carcinogenesis (Sano et al 1995). Although the exis-
tence of COX-3 has recently been reported, it continues to 
be debated.
LOX is the ﬁ  rst enzyme in the pathway for producing 
leukotriene (LT) from arachidonic acid. Isoenzymes of 
LOX include 5-LOX, 12-LOX, and two 15-LOX isoforms 
(15-LOX-1, 15-LOX-2). These catalyze the biosynthesis of 
biologically active compounds such as LTs and hydroxyeico-
satetraenoic acids (HETEs) (Sigal 1991; Funk 1996). 5-LOX 
catalyzes the ﬁ  rst step in oxygenation of arachidonic acid to 
produce 5-hydroperoxyeicosatetraenoic acid (5-HPETE), and 
the subsequent metabolism of 5-HPETE to 5-HETE and LTs 
(Figure 1). LTs belong to an important group of pro-inﬂ  am-
matory mediators that are synthesized from arachidonic 
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Figure 1 Map of arachidonic acid (AA) cascade. Cyclooxygenase (COX) is the ﬁ  rst enzyme in the pathway for producing prostaglandin (PG) and thromboxane (Tx) from 
arachidonic acid. COX-1 is present in most tissues and involved in the physiological production of PGs for maintaining normal homeostasis. COX-2, which is induced by 
mitogens, cytokines, and growth factors, is primarily responsible for PGs produced in inﬂ  ammatory sites. Lipoxygenase (LOX) is the ﬁ  rst enzyme in the pathway for producing 
leukotrien (LT) from arachidonic acid. Isoenzymes of LOX include 5-LOX, 12-LOX, and two 15-LOX isoforms (15-LOX-1, 15-LOX-2).Biologics: Targets & Therapy 2008:2(4) 727
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Figure 2  Mechanism of PPAR-γ ligand. PPAR-γ are members of the nuclear receptor super-family of ligand-activated transcriptional factor. PPAR binds to peroxisome proliferator 
response element (PPRE) as a heterodimer with the retinoic receptor (RXR), implying a role of 9-cis retinoic acid in PPAR target gene regulation.
to the formation of unstable LTA4, which can be converted 
into either LTB4, or cysteinyl LTs (LTC4, LTD4 and LTE4) 
(Matsuyama et al 2007).
The 12-LOX, includes platelet 12-LOX, and leukocyte 
12-LOX that oxygenate arachidonic acid at position C-12 
to produce 12-hydroperoxyeicosatetra-enoic acid and then 
12-HETE (Yoshimura et al 2003). Whereas 5-LOX, 12-LOX, 
and 15-LOX-1, have pro-carcinogenic roles, 15-LOX-2 
appears to have an anticarcinogenic role.
Peroxisome proliferator 
activator-receptor
Peroxisome proliferator activator-receptors are members of 
the nuclear receptor super-family of ligand-activated tran-
scriptional factor such as steroids, thyroid hormone, vitamin 
D3 and retinoic acid (Issemann and Green 1990). PPAR binds 
to peroxisome proliferator response element (PPRE) as a het-
erodimer with the retinoic receptor (RXR) in the regulation 
of PPAR target genes (Figure 2). PPARs may be important 
immunomodulatory factors as well as fatty acid regulators. 
PPARs modulate these activities in different immune cell 
types such as monocyte/macrophages, lymphocytes, and 
endothelial cells.
Three PPAR subtypes (α, β, and-γ) have been identi-
ﬁ  ed. PPAR-α is highly expressed in the liver, heart, kid-
ney, muscle, brown adipose tissue, and gut tissues which 
exhibit high carbolic rates towards fatty acid (Braissant 
et al 1996). PPAR-β is expressed ubiquitously, and its 
function is relatively unknown (Mukherjee et al 1997). 
Recent studies suggest that PPAR-β may be a target for 
NSAID-induced tumor suppression in colorectal tumors. 
PPAR-γ is expressed at high-level in adipose tissue and is 
a critical regular of adipocyte differentiation. In addition, 
PPAR-α, and –γ may be important immunomodulatory 
factors. PPAR-α-knockout mice exhibit exacerbated inﬂ  am-
matory responses, and LTB4, a chemotactic mediator, seems 
to regulate the clearance of itself as an agonist of PPAR-α. 
PPAR-γ is also expressed in the immune system tissues 
and cells (spleen, bone-marrow, monocytes, helper T-cell 
clones) and skeletal tissues (bone, synovioum, chondro-
cytes) (Braissant et al 1996).
Recent data have shown that PPAR-γ ligands lead to inhi-
bition of phorbol ester-induced nitric oxide and macrophage-
derived cytokines. PPAR-γ ligands also induce apoptosis in 
macrophage, ﬁ  broblasts, and endothelial cells (Kawahito et al 
2000). PPAR-γ plays a role in both adipocyte differentiation 
and carcinogenesis. PPAR-γ ligands lead to inhibition of 
the expression of nitric oxide, cytokines, chemokines and 
adhesion molecules, in part by antagonizing the activities of 
transcriptional factors. Furthermore, PPAR-γ ligands includ-
ing antidiabetic thiazolidinedione (such as troglitazone) and 
15-deoxy-Δ12,14 -prostaglandin J2 (15-d-PGJ2) have potent Biologics: Targets & Therapy 0000:0(0) 728
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tumor modulatory effects on several cancers (Tsubouchi 
et al 2000; Inoue K et al 2001).
COX and PC
COX-2 expression in PC tissues is stronger than in the 
normal prostate (NP), benign prostate hyperplasia (BPH), 
and prostatic intraepithelial neoplasia (PIN) tissues, whereas 
there are no signiﬁ  cant differences among COX-1 expression 
in NP, BPH, PIN, or PC tissues by immunohistochemical 
staining (28 PC, 1 PIN, 8 BPH and 8 NP tissues) or RT-
PCR (Figure 3). There were no signiﬁ  cant differences in the 
intensity of COX-1 among NP, BPH, PIN and PC tissues. 
However, only in epithelium of PC tissues, COX-2 expres-
sion was more intensive and extensive than that in NP, BPH 
and PIN tissues, and COX-2 expression was stronger in 
low differentiation PC (Yoshimura et al 2000). Gupta and 
colleagues (2000) reported COX-2 expression was stronger 
than COX-1 in PC by immunohistochemical staining and 
RT-PCR. Kirschenbaum and colleagues (2000) reported both 
COX-1 and COX-2 expressions in PC tissues were stronger 
than those in NP tissues by immunohistochemical staining.
Vascularization of tumors is closely linked to the 
expression of COX-2 in tumors. Apoptosis is induced in 
tumor cell in response to drugs which inhibit vasculariza-
tion. Angiogenesis factors such as vascular endothelial 
growth factor and transforming growth factor beta are 
induced by COX-2 expression. Liu and colleagues (2000) 
reported suppressing vascular endothelial growth factor and 
inducing apoptosis in nude mouse xenografts of the human 
PC cell line (PC3) with three intraperitoneal injection 
of the COX-2 inhibitor NS398 (3 mg/kg) over 9 week. In 
these studies, Bcl-2 was found to be a key apoptosis sup-
pressing factor. In contrast, Hsu and colleagues (2000) 
reported that growth inhibition of PC-3 and LNCaP cells 
by selective COX-2 inhibitor celecoxib was associated 
with down-regulation of Bcl-2. COX-2 inhibition results in 
down-regulation of the nuclear factor-λB, or the activation 
of PPAR-γ, apoptosis activating factor-1, and caspase-3 
(Narayanan et al 2003).
A recently accepted explanation is that only celecoxib, 
among the COX-2 inhibitors induces apoptosis of cancer cells. 
Andrews and colleagues (2008) reported celecoxib was most 
effective in decreasing cell growth and inducing apoptosis 
at the lowest dosages in several NSAIDs. Narayanan and 
colleagues (2006) reported celecoxib had a dose-dependent 
effect against transgenic adenocarcinoma in mouse prostate. 
Patel and colleagues (2005) reported the anticancer activity 
of celecoxib may reﬂ  ect COX-2-independent in addition to 
COX-2-dependent effects.
In our experiment, we could not demonstrate signiﬁ  cant 
apoptosis induction by administering eight kinds of COX-2 
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Figure 3 RT-PCR analysis of COX-1 and COX-2 in prostate tissues. We detected the speciﬁ  c band of COX-1 protein in all samples (A, lane 2, 3, 4). However, we detected 
the speciﬁ  c band of COX-2 protein in samples from prostate cancer (B, lane 4), while a sample from BPH displayed a very weak band (B, lane 3), and a sample from normal 
prostate displayed no clear band (B, lane 2) in the study.Biologics: Targets & Therapy 2008:2(4) 729
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Additionally, we could not demonstrate the signiﬁ  cance of 
both selective COX-2 inhibitor and relatively poor selective 
COX-2 inhibitor (Yoshimura et al 2004).
In conclusion, COX-2 expression is strong in PC, but the 
anticancer effect of COX-2 inhibitor is very weak in PC and 
hormone-refractory PC patients in a single administration at 
a clinical dose. COX-2 inhibitor is suitable for chemopre-
ventive therapy.
LOX and PC
We have shown that 5- and 12-LOX expressions in PC 
and PIN tissue are stronger than those in NP and BPH tis-
sues by immunohistochemical staining (174 PC, 20 PIN, 
20 BPH, and 20 NP tissues) and RT-PCR. We classiﬁ  ed 
3 categories (epithelium, blood vessel, stromal tissue) in 
NP, BPH, PIN, and PC tissues, and examined the intensity 
of 5- and 12-LOX expressions. 5- and 12-LOX expressions 
were more intensive and extensive in all categories of PC 
and PIN tissues as compared with NP and BPH tissues 
(Table 2). There were no signiﬁ  cant differences between 
5- and 12-LOX expressions in grades (Matsuyama et al 
2004a). Consistent with our ﬁ  ndings, Kelavkar and col-
leagues (2004) reported 15-LOX-1 is expressed in NP and 
increased in PC, especially high-grade PC. At 10–80 μM, 
some, but not all LOX inhibitors reduced the viability of 
PC3 and DU-145 cell lines by MTT assay (Table 1). Some 
Table 1 Effects of COX and LOX inhibitors, and PPAR-γ ligand in viability of human prostate cancer cells
COX inhibitors PC cel line 5μM1 0 μM2 0 μM4 0 μM8 0 μM
Etodolac PC3 not shown 93.6% 88.3% 89.1% 77.5%
DU-145 not shown 105.1% 106.7% 104.4% 95.1%
Nimesulide PC3 not shown 83.1% 91.5% 78.1% 94.1%
DU-145 not shown 110.1% 99.1% 99.8% 105.9%
LOX inhibitors
5-LOX inhibitor PC3 not shown 112.5% 96.7% 78.8% 45.3%
DU-145 not shown 80.7% 69.2% 22.2% 8.1%
12-LOX inhibitor PC3 not shown 117.8% 100.2% 103.8% 76.5%
DU-145 not shown 102.4% 99.1% 85.1% 63.5%
Non selective LOX inhibitor PC3 not shown 113.0% 101.7% 51.1% 18.5%
DU-145 not shown 67.7% 42.3% 9.9% 5.2%
PPAR-γ ligands
Troglitazone PC3 48.6% 15.5% 14.7% 6.5% not shown
DU-145 60.1% 35.1% 7.6% 7.7% not shown
15d-PGJ2 PC3 69.7% 59.0% 34.1% 6.8% not shown
 DU-145 73.8% 59.3% 5.8% 5.8% not  shown
Notes:  The dose-response analysis of viability in human prostate cancer cells treated with COX and LOX inhibitors, and PPAR-γ ligands (5-80μM, 48hr) was measured by the 
MTT assay and expressed as % of control culture conditions.
Table 2 Statistical analysis of 5-LOX and 12-LOX immunostaining
 Epithelium Blood  vessel Stromal tissue
5-LOX
PC 2.5 ± 1.1* 2.2 ± 1.0* 2.2 ± 0.9*
Low group 2.2 ± 1.4* 2.2 ± 1.4* 2.0 ± 0.8*
Middle group 2.7 ± 1.0* 2.7 ± 1.0* 2.2 ± 1.2*
High group 2.6 ± 1.2* 2.6 ± 1.2* 2.4 ± 0.7*
PIN 2.1 ± 1.1* 2.0 ± 1.4* 1.9 ± 1.1*
BPH 0.5 ± 0.5 0.6 ± 0.5 0.6 ± 0.5
NP 0.5 ± 0.5 0.5 ± 0.5 0.5 ± 0.4
12-LOX
PC 2.2 ± 1.0* 2.2 ± 1.2* 2.2 ± 0.9*
Low group 2.0 ± 1.2* 2.0 ± 1.2* 1.8 ± 0.7*
Middle group 2.4 ± 1.2* 2.4 ± 1.2* 2.6 ± 1.0*
High group 2.3 ± 0.9* 2.3 ± 0.9* 2.2 ± 0.9*
PIN 1.9 ± 1.3* 1.8 ± 1.4* 1.8 ± 1.1*
BPH 0.8 ± 0.5 0.7 ± 0.5 0.5 ± 0.5
NP 0.6 ± 0.4 0.5 ± 0.4 0.5 ± 0.4
LOX inhibitors induced apoptosis in PC cells at 50 μM. 
5-LOX inhibitor appeared more potent than the 12-LOX 
inhibitor (Matsuyama et al 2004a, 2004b).
Several papers have reported that LOX inhibitors are 
candidates for the development as new chemopreventive 
or chemotherapeutic strategies for PC. Ghosh and Myers Biologics: Targets & Therapy 2008:2(4) 730
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(1998) reported that inhibition of arachidonate 5-LOX triggers 
massive apoptosis in both androgen-sensitive (LNCaP) and 
androgen-refractory (PC3) human PC cells. The metabolites 
of arachidonate 5-LOX promoted survival of PC cells 
involving down-regulation of stress-activated protein kinase 
(Ghosh 2003). Furthermore, concern about combination 
5-LOX inhibitor and other target, Pommery and colleagues 
(2004) reported dual COX-2/5-LOX inhibitors induce agents 
potentially useful in prostate cancer chemotherapy through 
apoptosis (Pommery et al 2004). Ghosh J et al reported the 
combination of selenium and 5-LOX inhibitors may be a more 
effective regimen for PC control (Ghosh 2004). Narayanan 
and colleagues (2007) reported Licofelone inhibited COX-2 
and 5-LOX simultaneously and prevented overall cancer cell 
growth by enhancing apoptosis in both androgen-dependent and 
androgen-independent PC cells. Yoshida and colleagues (2007) 
reported LOX inhibitors augment the apoptotic efﬁ  ciency of 
tumor necrosis factor-related apoptosis-inducing ligand through 
death receptor 5 up-regulation in malignant tumor cells.
In conclusion, 5-LOX expression is strong in PC, 
especially high-grade PC. The anticancer effect of 5-LOX 
inhibitor is significantly stronger than those of COX-2 
inhibitor. The anticancer effect of 5-LOX inhibitor is weak 
in PC and hormone-refractory PC patients in a single admin-
istration at a clinical dose. 5-LOX inhibitor is suitable for 
chemopreventative therapy like the COX-2 inhibitor.
PPAR -γ and PC
By immunohistochemical staining (Figure 4), and RT-PCR, 
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Figure 4 Representative immunostaining for PPAR-γ in prostate tissues samples. We detected signiﬁ  cant strong PPAR-γ expression in all  PC (D; G1, E; G2, F, G3) group tissues 
and PIN (C) tissue, whereas PPAR-γ expression was very weak in BPH (B) tissue and NP (A) tissue.Biologics: Targets & Therapy 2008:2(4) 731
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compared with BPH and NP tissues (156 PC, 15 PIN, 20 BPH, 
and 12 NP tissues). In epithelium, blood vessel, stromal tissue 
of PC, PIN, BPH, and NP tissues, the intensity of PPAR-α, -β, 
and –γ expression was not signiﬁ  cantly different. In the paren-
chyma, PPAR-γ expression was signiﬁ  cantly greater in PC and 
PIN tissues than in BPH and NP tissues. In our studies, PPAR-γ 
expression was higher in G3 cancer than in G1 cancer (Segawa 
et al 2002). In contrast, Paltoo and colleagues (2003) were 
unable to detect signiﬁ  cant differences in PPAR-γ expression 
across grades and stages, perhaps due to technical limitations.
The PPAR-γ ligands troglitazone and 15-d-PGJ2 induced 
the reduction of PC3 and DU-145 viability in the range of 
10–40μM by using MTT assay (Table 1). PC cells treated 
with PPAR-γ ligands (25 μM troglitazone and 15-d-PGJ2) 
entered early apoptosis, but not late apoptosis, necrosis or 
DNA fragmentation by ﬂ  ow cytometry (Figure 5) (Matsuyama 
and Yoshimura 2008). However, PPAR-γ ligands did not 
cause normal prostate epithelial cells to undergo apoptosis. 
Subbarayan and colleagues (2004) also reported similar results. 
Several reports support a similar degree of efﬁ  cacy of PPAR-γ 
ligands in PC (Butler et al 2000; Chaffer et al 2006).
In conclusion, PPAR-γ is strongly expressed in PC, and the 
anticancer effect of PPAR-γ ligand is signiﬁ  cantly greater than 
that of 5-LOX inhibitor. The anticancer effect of PPAR-γ ligand 
is relatively week. Targeting PPAR-γ in PC is likely to be useful 
more as a chemopreventive rather than a chemotherapeutic.
Conclusions
There is no argument that COX-2, LOX (especially, 5-LOX) 
PPAR-γ are involved in the initiation and promotion of PC 
tissues. It may be possible to use COX-2 and 5-LOX inhibitors, 
and PPAR-γ ligand as anticancer drugs for chemopreventive 
therapy in a single administration of a clinical dose. However, 
it may be difﬁ  cult to use COX-2 and 5-LOX inhibitors, even 
with PPAR-γ ligand in single administration of a clinical 
dose as a potential chemotherapeutic therapy. The clinical 
application of PPAR-γ ligand and 5-LOX inhibitor require 
further research and consideration, as the target of PPAR-γ 
ligand and 5-LOX inhibitor remains a novel strategy in treat-
ing human PC.
We conclude the administration of COX-2 and 5-LOX 
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Figure 5 Effects of PPAR-γ ligands on apoptosis by ﬂ  ow cytometry in PC cell line. Treatment with 25μM PPAR-γ ligands (troglitazone and 15-d-PGJ2) induced early apoptosis 
not late apoptosis or necrosis in PC cell line (PC3). The top left quadrants represent early apoptosis. Diagrams of FITC-Annexin V/PI ﬂ  ow cytometry are presented (A). 
Treatment with 25 μM PPAR-γ ligands (troglitazone and 15-d-PGJ2) could induce DNA fragmentation in PC cell line (PC3). Typical ﬂ  ow cytometry analysis histograms are 
presented (B).Biologics: Targets & Therapy 2008:2(4) 732
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treatment of human PC. The combination therapy of COX-2 
and 5-LOX inhibitor, and PPAR-γ ligand may be a beneﬁ  cal 
new treatment of human PC.
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